NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT00515528 2021-01-26
Vaccination Plus Ontak in Patients With Metastatic Melanoma
University of Chicago
Phase 2 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT01773889 2018-04-10
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT01251952 2017-06-20
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT00726037 2016-09-29
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
Loyola University
Phase 2 Terminated